# Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)

> **NCT00292071** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Fungal Infection

## Interventions

- **DRUG:** caspofungin acetate

## Key facts

- **NCT ID:** NCT00292071
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00292071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00292071, "Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00292071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*